Endothelin receptor blocker bosentan inhibits hypertensive cardiac fibrosis in pressure overload-induced cardiac hypertrophy in rats

Cardiovascular Endocrinology

Volumn 2, Issue 4, 2013, Pages 85-97

  Visnagri, Asjad ^a   Kandhare, Amit D ^a   Ghosh, Pinaki ^a   Bodhankar, Subhash L ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Bosentan; Cardiac hypertrophy; Endothelin 1; Hypertension; Reactive oxygen species; Tumor necrosis factor

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATE; BIOCHEMICAL MARKER; BOSENTAN; CREATINE KINASE MB; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; GLUTATHIONE; HYDROXYPROLINE; LACTATE DEHYDROGENASE; MALONALDEHYDE; PHOSPHATE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL AORTA; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG INHIBITION; ECG ABNORMALITY; ELECTROCARDIOGRAM; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; HYPERTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULSE PRESSURE; RAT; UPREGULATION;

EID: 84899693160     PISSN: None     EISSN: 2162688X     Source Type: Journal    
DOI: 10.1097/XCE.0000000000000010     Document Type: Article

References (92)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
2. Dole S, Kandhare AD, Ghosh P, Gosavi TP, Bodhankar SL. The health outcome after homeopathic treatment in cases of BPH and LUTS: a prospective clinical study. J Pharm Biomed Sci 2012; 22:1-6.
3. Imamura M, Schluchter M, Fouad-Tarazi FM. Remodelling of left ventricle after banding of ascending aorta in the rat. Cardiovasc Res 1990; 24:641-646.
4. Norton GR, Woodiwiss AJ, Gaasch WH, Mela T, Chung ES, Aurigemma GP, et al. Heart failure in pressure overload hypertrophy: the relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol 2002; 39:664-671.
5. Stoyanova V, Zhelev NZ, Yanev IB, Ghenev ED, Nachev CK. Time course and progression of pressure overload-induced cardiac hypertrophy in rats. Folia Med (Plovdiv) 2005; 47:52.
6. Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995; 96:1093-1099.
7. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003; 41:2164-2171.
8. Patil MVK, Kandhare AD, Ghosh P, Bhise SD. Determination of role of GABA and nitric oxide in anticonvulsant activity of Fragaria vesca L. ethanolic extract in chemically induced epilepsy in laboratory animals. Orient Pharm Exp Med 2012; 12:255-264.
9. Kandhare AD, Raygude KS, Ghosh P, Gosavi TP, Bodhankar SL. Patentability of animal models: India and the globe. Int J Pharma Biol Arch 2011; 2:1024-1032.
10. Oh H, Wang SC, Prahash A, Sano M, Moravec CS, Taffet GE, et al. Telomere attrition and Chk2 activation in human heart failure. Proc Natl Acad Sci USA 2003; 100:5378-5383.
11. Sia YT, Lapointe N, Parker TG, Tsoporis JN, Deschepper CF, Calderone A, et al. Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation 2002; 105:2549-2555.
12. Choudhary R, Baker KM, Pan J. All-trans retinoic acid prevents angiotensin II- and mechanical stretch-induced reactive oxygen species generation and cardiomyocyte apoptosis. J Cell Physiol 2008; 215:172-181.
13. Ghule AE, Kulkarni CP, Bodhankar SL, Pandit VA. Effect of pretreatment with coenzyme Q10 on isoproterenol-induced cardiotoxicity and cardiac hypertrophy in rats. Curr Ther Res Clin Exp 2009; 70:460-471.
14. Hirata Y, Yoshimi H, Takaichi S, Yanagisawa M, Masaki T. Binding and receptor down-regulation of a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. FEBS Lett 1988; 239:13-17.
15. Suzuki T, Hoshi H, Mitsui Y. Endothelin stimulates hypertrophy and contractility of neonatal rat cardiac myocytes in a serum-free medium. FEBS Lett 1990; 268:149-151.
16. McDonough PM, Brown JH, Glembotski CC. Phenylephrine and endothelin differentially stimulate cardiac PI hydrolysis and ANF expression. Am J Physiol 1993; 264:H625-H630.
17. Abraham A, Kay J, Cole R, Pincock AC. Haemodynamic and pathological study of the effect of chronic hypoxia and subsequent recovery of the heart and pulmonary vasculature of the rat. Cardiovasc Res 1971; 5:95-102.
18. Yin F, Spurgeon H, Weisfeldt M, Lakatta EG. Mechanical properties of myocardium from hypertrophied rat hearts. A comparison between hypertrophy induced by senescence and by aortic banding. Circ Res 1980; 46:292-300.
19. Grossman W. Cardiac hypertrophy: useful adaptation or pathologic process? Am J Med 1980; 69:576-584.
20. Drayer JIM, Weber MA, Gardin JM, Lipson JL. Effect of long-term antihypertensive therapy on cardiac anatomy in patients with essential hypertension. Am J Med 1983; 75:116-120.
21. Wollam GL, Hall W, Porter VD, Douglas MB, Unger DJ, Blumenstein BA, et al. Time course of regression of left ventricular hypertrophy in treated hypertensive patients. Am J Med 1983; 75:100-110.
22. Jiang J, Yuen V, Xiang H, McNeill JH. Improvement in cardiac function of diabetic rats by bosentan is not associated with changes in the activation of PKC isoforms. Mol Cell Biochem 2006; 282:177-185.
23. Kaddoura S, Firth JD, Boheler KR, Sugden PH, Poole-Wilson PA. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo: acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation 1996; 93:2068-2079.
24. Roux S, Breu V, Ertel SI, Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J Mol Med 1999; 77:364-376.
25. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996; 60:124-137.
26. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002; 39:1567-1573.
27. Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000; 102:411-418.
28. Kiowski W, Sütsch G, Hunziker P, Müller P, Kim J, Oechslin E, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346:732-736.
29. Underwood DC, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW. Nonpeptide endothelin receptor antagonists. X. Inhibition of endothelin-1-and hypoxia-induced pulmonary pressor responses in the guinea pig by the endothelin receptor antagonist, SB 217242. J Pharmacol Exp Ther 1997; 283:1130-1137.
30. Cosenzi A, Bernobich E, Trevisan R, Milutinovic N, Borri A, Bellini G. Nephroprotective effect of bosentan in diabetic rats. J Cardiovasc Pharmacol 2003; 42:752-756.
31. Evans T, Deng DX, Chen S, Chakrabarti S. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats]. Diabetes 2000; 49:662-666.
32. van Deel ED, de Boer M, Kuster DW, Boontje NM, Holemans P, Sipido KR, et al. Exercise training does not improve cardiac function in compensated or decompensated left ventricular hypertrophy induced by aortic stenosis. J Mol Cell Cardiol 2011; 50:1017-1025.
33. Said SA, Ammar el SM, Suddek GM. Effect of bosentan (ETA/ETB receptor antagonist) on metabolic changes during stress and diabetes. Pharmacol Res 2005; 51:107-115.
34. Misera H, Fridovich I. The role of superoxide anion in the auto-oxidation of epinephrine and a simple assay for SOD. J Biol Chem 1972; 247:3170-3175.
35. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta 1979; 582:67-78.
36. Slater T, Sawyer B. The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. General features of the systems used. Biochem J 1971; 123:805.
37. Bonting S. Presence of enzyme system in mammalian tissues. Membrane and Ion Transport. In: Bilter EE, editor. Presence of enzyme systems in mammalian tissues. London: Wiley Interscience; 1970. pp. 257-263.
38. 2+-ATPase from erythrocyte membranes. Biochim Biophys Acta 1983; 728:281-288.
39. Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem 1925; 66:375-400.
40. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
41. Neuman RE, Logan MA. The determination of collagen and elastin in tissues. J Biol Chem 1950; 186:549-556.
42. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 1982; 126:131-138.
43. Konturek PC, Duda A, Brzozowski T, Konturek SJ, Kwiecien S, Drozdowicz D, et al. Activation of genes for superoxide dismutase, interleukin-1beta, tumor necrosis factor-alpha, and intercellular adhesion molecule-1 during healing of ischemia-reperfusion-induced gastric injury. Scand J Gastroenterol 2000; 35:452-463.
44. Brown LA, Nunez DJ, Brookes CI, Wilkins MR. Selective increase in endothelin-1 and endothelin A receptor subtype in the hypertrophied myocardium of the aorto-venacaval fistula rat. Cardiovasc Res 1995; 29:768-774.
45. Kang PM, Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res 2000; 86:1107-1113.
46. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction The Framingham Heart Study. Circulation 2003; 107:1486-1491.
47. Liang Q, Molkentin JD. Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol 2003; 35:1385-1394.
48. Nishida K, Yamaguchi O, Hirotani S, Hikoso S, Higuchi Y, Watanabe T, et al. p38a mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol Cell Biol 2004; 24:10611-10620.
49. Boluyt MO, Robinson KG, Meredith AL, Sen S, Lakatta EG, Crow MT, et al. Heart failure after long-term supravalvular aortic constriction in rats. Am J Hypertens 2005; 18:202-212.
50. Martino RF, Davicino RC, Mattar MA, Casali YA, Correa SG, Micalizzi B. Larrea divaricata Cav. enhances the innate immune response during the systemic infection by Candida albicans. Afr J Microbiol Res 2011; 5:753-761.
51. Rahimkhani M, Khavari-Daneshvar H, Jamali S. Serologic evaluation of hepatitis B and D in patients with cirrhosis [J]. Afr J Microbiol Res 2011; 5:568-571.
52. Dahl LK, Heine M, Tassinari L. Role of genetic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. Nature 1962; 194:480-482.
53. Bing O. Hypothesis: apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. J Mol Cell Cardiol 1994; 26:943-948.
54. Pfeffer JM, Pfeffer MA, Fishbein MC, Frohlich ED. Cardiac function and morphology with aging in the spontaneously hypertensive rat [J]. Am J Physiol 1979; 237:H461-H468.
55. Basil B, Jordan R, Loveless A, Maxwell DR. A comparison of the experimental anti-arrhythmic properties of acebutolol:(M & B 17803), propranolol and practolol. Br J Pharmacol 2012; 50:323-333.
56. Kandhare AD, Ghosh P, Ghule AE, et al. Elucidation of molecular mechanism involved in neuroprotective effect of Coenzyme Q10 in alcohol induced neuropathic pain. Fundam Clin Pharmacol 2013. doi: 10.1111/fcp.12003. [Epub ahead of print].
57. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79:215-262.
58. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105:2867-2871.
59. Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Tanaka M, et al. Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest 1997; 100:1813.
60. von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 1999; 99:2934-2941.
61. Farquharson CAJ, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure [J]. Circulation 2002; 106:221-226.
62. Kandhare AD, Ghosh P, Ghule AE, Zambare GN, Bodhankar SL. Protective effect of Phyllanthus amarus by modulation of endogenous biomarkers and DNA damage in acetic acid induced ulcerative colitis: role of phyllanthin and hypophyllanthin. Apollo Med 2013; 10:87-97.
63. Kandhare AD, Kumar VS, Adil M, Rajmane AR, Ghosh P, Bodhankar SL. Investigation of gastro protective activity of Xanthium strumarium L. by modulation of cellular and biochemical marker. Orient Pharm Exp Med 2012; 12:287-299.
64. Patil MVK, Kandhare AD, Bhise SD. Anti-arthritic and anti-inflammatory activity of Xanthium srtumarium L. ethanolic extract in Freund's complete adjuvant induced arthritis. Biomed Aging Pathol 2012; 2:6-15.
65. Rathore N, John S, Kale M, Bhatnagar D. Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues. Pharmacol Res 1998; 38:297-303.
66. Srivastava S, Chandrasekar B, Gu Y, Luo J, Hamid T, Hill BG, Prabhu SD. Downregulation of CuZn-superoxide dismutase contributes to b-adrenergic receptor-mediated oxidative stress in the heart. Cardiovasc Res 2007; 74:445-455.
67. Raygude KS, Kandhare AD, Ghosh P, Ghule AE, Bodhankar SL. Evaluation of ameliorative effect of quercetin in experimental model of alcoholic neuropathy in rats. Inflammopharmacology 2012; 20:331-341.
68. Hemnani T, Parihar M. Reactive oxygen species and oxidative DNA damage. Indian J Physiol Pharmacol 1998; 42:440-452.
69. Gosavi TP, Kandhare AD, Ghosh P, et al. Anticonvulsant activity of Argentum metallicum, a homeopathic preparation. Der Pharmacia Lettre 2012; 4:626-637.
70. Kandhare A, Raygude K, Ghosh P, Bodhankar SL. The ameliorative effect of fisetin, a bioflavonoid, on ethanol-induced and pylorus ligation-induced gastric ulcer in rats. Int J Green Pharm 2011; 5:236-243.
71. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996; 28:506-514.
72. Kandhare AD, Raygude KS, Ghosh P, Ghule AE, Bodhankar SL. Neuroprotective effect of naringin by modulation of endogenous biomarkers in streptozotocin induced painful diabetic neuropathy. Fitoterapia 2012; 83:650-659.
73. Kandhare AD, Raygude KS, Ghosh P, Ghule AE, Bodhankar SL. Therapeutic role of curcumin in prevention of biochemical and behavioral aberration induced by alcoholic neuropathy in laboratory animals. Neurosci Lett 2012; 511:18-22.
74. Kandhare AD, Raygude KS, Shiva Kumar V, Rajmane AR, Visnagri A, Ghule AE, et al. Ameliorative effects quercetin against impaired motor nerve function, inflammatory mediators and apoptosis in neonatal streptozotocin-induced diabetic neuropathy in rats. Biomed Aging Pathol 2012; 2:173-186.
75. + regulation in normal and failing hearts. J Pharmacol Sci 2006; 100:315-322.
76. 2+ handling in heart failure. J Clin Invest 2005; 115:556-564.
77. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006; 124:207-219.
78. Di Lisa F, Menabò R, Canton M, Petronilli V. The role of mitochondria in the salvage and the injury of the ischemic myocardium. Biochim Biophys Acta 1998; 1366:69-78.
79. Raygude KS, Kandhare AD, Ghosh P, Bodhankar SL. Anticonvulsant effect of fisetin by modulation of endogenous biomarkers. Biomed Prev Nutr 2012; 2:215-222.
80. Kandhare AD, Raygude KS, Ghosh P, Ghule AE, Gosavi TP, Badole SL, et al. Effect of hydroalcoholic extract of Hibiscus rosa sinensis Linn. leaves in experimental colitis in rats. Asian Pac J Trop Biomed 2012; 5:337-344.
81. Kennedy D, Omran E, Periyasamy SM, Nadoor J, Priyadarshi A, Willey JC, et al. Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat. J Am Soc Nephrol 2003; 14:90-97.
82. Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, et al. Tumor necrosis factor - α mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007; 115:1398-1407.
83. Kerkela R, Force T. p38 mitogen-activated protein kinase: a future target for heart failure therapy? J Am Coll Cardiol 2006; 48:556-558.
84. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257:5387.
85. Schulz R, Panas DL, Catena R, Moncada S, Olley PM, Lopaschuk GD. The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha [J]. Br J Pharmacol 1995; 114:27-34.
86. Sakurai T, Yanagisawa M, Inoue A, Ryan US, Kimura S, Mitsui Y, et al. cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA. Biochem Biophys Res Commun 1991; 175:44-47.
87. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993; 92:398-403.
88. Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T, et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991; 69:209-215.
89. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 1990; 265:20555-20562.
90. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102:2434-2440.
91. Clozel M, Breu V, Burri K, Cassal JM, Fischli W, Gray GA, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365:759-761.
92. Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270:228-235.